Diabetes and Vascular Disease

MTP31 - Use of Adjunctive Therapies to Target Cardiometabolic Risk in Type 1 Diabetes

Monday, June 15, 2026

2:35 PM - 3:15 PM CT

Location: Room W375A

Meet the Professor Speaker(s)

Jerry R. Greenfield, MBBS, PhD, FRACP

Endocrinologist
Victor Chang Cardiac Research Institute
Sydney, Australia

Disclosure(s):

Jerry R. Greenfield, MBBS, PhD, FRACP: Novo Nordisk: Recipient of drug and placebo for a study of semaglutide in type 1 diabetes ()

Explain the pathophysiological mechanisms that contribute to increased cardiovascular (CV) risk in people with type 1 diabetes (T1D).
Identify type 2 diabetes (T2D) medications that may be beneficial as adjunctive cardiometabolic agents in individuals with T1D.
Safely manage patients with T1D who start off-label adjunctive cardiometabolic agents.